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Abstract
Background: Decline of renal function is common in older persons and the prevalence of chronic kidney disease
(CKD) is rising with ageing. CKD affects different outcomes relevant to older persons, additionally to morbidity and
mortality which makes CKD a relevant health burden in this population. Still, accurate laboratory measurement of
kidney function is under debate, since current creatinine-based equations have a certain degree of inaccuracy when
used in the older population. The aims of the study are as follows: to assess kidney function in a cohort of 75+
older persons using existing methodologies for CKD screening; to investigate existing and innovative biomarkers of
CKD in this cohort, and to align laboratory and biomarker results with medical and functional data obtained from
this cohort. The study was registered at ClinicalTrials.gov, identifier NCT02691546, February 25th 2016.
Methods/design: An observational, multinational, multicenter, prospective cohort study in community dwelling
persons aged 75 years and over, visiting the outpatient clinics of participating institutions. The study will enroll 2450
participants and is carried out in Austria, Germany, Israel, Italy, the Netherlands, Poland and Spain. Participants will
undergo clinical and laboratory evaluations at baseline and after 12 and 24 months- follow-up. Clinical evaluation
also includes a comprehensive geriatric assessment (CGA). Local laboratory will be used for ‘basic’ parameters
(including serum creatinine and albumin-to-creatinine ratio), whereas biomarker assessment will be conducted
centrally. An intermediate telephone follow-up will be carried out at 6 and 18 months.
Discussion: Combining the use of CGA and the investigation of novel and existing independent biomarkers within
the SCOPE study will help to provide evidence in the development of European guidelines and recommendations
in the screening and management of CKD in older people.
Trial registration: This study was registered prospectively on the 25th February 2016 at clinicaltrials.gov
(NCT02691546).
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Background
Evidence from epidemiological and clinical literature
suggests that ageing contributes to the incidence of re-
duced renal filtration capacity [1]. In the presence of risk
factors during ageing, such as diabetes, hypertension and
others, filtration capacity further declines. This concept
is underlined by many epidemiological studies showing a
decline of measured estimated glomerular filtration rate
(eGFR) with advancing age [2]. Kidney function is usu-
ally assessed by creatinine-based estimated glomerular
filtration rate (eGFR) equations. However, those formu-
lae have a certain degree of inaccuracy when used in
older people due to changes in anthropometry and renal
physiology during ageing [3]. Alternative filtration
markers yielded different eGFR values for different co-
horts of people tested [4]. This inaccuracy of laboratory
measurements of kidney function suggests a risk of
underdetection or overdetection of CKD, especially with
advancing age [5]. Indeed, the eGFR threshold at which
the risk of negative outcomes increases among older pa-
tients is hotly debated [6], and current evidence suggests
that such a threshold may be lower among older people
compared to adult ones [7–9]. Additionally, the eGFR
cut-offs at which the risk of death starts to increase may
change as a function of the equation used among older
people [10]. Thus, improving accuracy of CKD screening
measures for older populations would be of help in re-
ducing the risk of underdiagnosis to maximize preven-
tion of CKD and its consequences while minimising the
risks and cost of overdiagnosis [6].
Diminished kidney function has become a relevant pub-
lic health burden for all age groups, as CKD frequently re-
sults in an increased risk of end stage renal disease
(ESRD), morbidity and mortality [11]. Besides “traditional”
endpoints, CKD has been shown to impact nutritional sta-
tus, inflammatory processes and anemia [12], thereby af-
fecting different outcomes especially relevant to older
people. These include impaired physical function, frailty
and disability [13–16], cognitive impairment and dementia
[17–19], depression [20–22], sensory impairment [23], un-
dernutrition and sarcopenia [24–26], and adverse drug re-
actions (ADRs) [27, 28]. Therefore, early and sensitive
detection of diminished renal function is essential to indi-
vidually address care needs of older people with CKD and
to address one of the major health burden in public health
for the incoming decades [29].
Incorporating scoring risk models for care planning of
older people at risk for CKD has come into focus re-
cently [30]. Risk prediction models are generally based
on equations designed on the basis of prognostic factors
and clinical outcomes, available at the time the predic-
tion is made, and collected in specific and representative
cohorts of individuals followed up for a given period of
time [31]. Built on evidence of such models, screening
programmes for CKD can take into account the charac-
teristics of the target population in addition to simple la-
boratory measures, biomarkers and disease-based
investigations. Multi- and co-morbidity, polypharmacy,
frailty, functional and cognitive impairment and disabil-
ity should be considered as part of a patient centered ap-
proach in CKD management especially in older adults
[15, 23–26, 32–35].
So far, no CKD screening program has included all
those variables also including data from comprehensive
geriatric assessment (CGA), the only assessment tech-
nology able to capture the numerous domains of health
status and their complex interactions in older people.
Accordingly, the need for laboratory measurements able
to identify accurately older people with CKD is a de-
mand to address the public health challenges arising
from the current demographic shifts. Indeed, this view is
widely shared by the geriatric and nephrology communi-
ties, both in EU and USA [36, 37].
The aims of this multicenter study in Europe are to as-
sess existing methodologies for CKD screening and in-
vestigate existing and innovative biomarkers of CKD in
older persons. Furthermore, the Screening for CKD
among Older People across Europe (SCOPE) study will
provide evidence for including physical and functional
health parameters of older people across Europe and
help design a tailored risk prediction model for CKD in
old age.
Methods
Study design
The SCOPE study is designed as an observational, multi-
national, multicenter, prospective cohort study in persons
older than 75 years across Europe. This study is carried
out in seven countries, including Austria, Germany, Israel,
Italy, the Netherlands, Poland and Spain. Participants will
undergo clinical and laboratory evaluations at the baseline
(recruitment), and will be followed up at face to face visits
at months 12 and 24 following enrollment. An intermedi-
ate telephone follow-up will be carried out at 6 and
18 months following recruitment. Figure 1 shows the
schematic flow of the observational clinical study.
The study design complies with the Declaration of
Helsinki and Good Clinical Practice Guidelines. The en-
rollment has started in August 2016 and is ongoing.
Ethical approval/ monitoring
The study protocol was approved by ethics committees
at all participating institutions. Patients are requested to
sign a written informed consent before entering the
study. Patients are also asked to sign a separate informed
consent to the collection of DNA samples to be used for
genetic testing, while those not giving their consent will
be retained in the main cohort study.
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In order to ensure high ethical and scientific standards
of the project and to monitor the progress of the clinical
study a Scientific Advisory Board (SAB) and a Data and
Ethics Management Board (DEMB) was implemented
within the Governance Structure. The SAB ensures a
high standard of research, monitors the progress of the
project by taking part in the project meetings, and pro-
vides final approval to any required study amendments.
The DEMB supports the preparation of the relevant
end-points for ethical review, advises on local research
Ethical Committee applications, and reviews the relevant
safety, morbidity and mortality end-points during the
course of the study. The DEMB maintains an overview
of the work throughout the whole course of the project
and helps to foresee possible problems that might arise
and how they can be addressed.
Study population
Persons aged 75 years and older, visiting the outpatient
clinics of participating institutions are eligible for inclu-
sion. The study design aims at minimizing self-selection
bias and enrolling real-world patients without stringent
inclusion/exclusion criteria. The few exclusion criteria
are outlined in Table 1. Therefore, no other inclusion
criteria will be considered. The SCOPE study aims to fi-
nally enroll 2450 participants.
Study visits
Following enrollment, participants will be seen by the
study teams at 12 and 24 months at a face to face meet-
ing. Demographic data and socioeconomic status (occu-
pation before retiring, economic status, formal and
informal care) will be documented and followed up at
each visit. Physical examination will be performed by
medical doctors due to standardized procedure given in
the visit protocol. Medical history and use of medication
and adverse drug reactions classified according to the
World Health Organization (WHO) definition [38] will
be collected during follow-up visits. During all face to
face visits a comprehensive geriatric assessment (CGA)
will be performed. Table 2 shows all domains checked
during study visits [39–51] [52].
Healthcare resource consumption will be evaluated
using a resource use questionnaire within a 6-month
recall time-frame [50]. Following information will be
retrieved: previous physician visits (GPs, specialists, or
physician at the Emergency Room), use of diagnostic
tests and specialist clinic procedures, use of care ser-
vices (e.g. Nurse home visit, Physiotherapy, Home
help, Social transport, Day care center) and hospital
admissions (number and duration of hospitalization,
type of reimbursement).
Furthermore, caregiver burden will be measured using
the Zarit Burden Interview (ZBI) [53].
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Fig. 1 Study design of the SCOPE project
Table 1 Exclusion criteria for participants enrollment into the
SCOPE project
• Age < 75 years
• End stage renal disease (< 15 mL/min/1.73 m2) or dialysis at time of
enrollment
• History of solid organ or bone marrow transplantation
• Active malignancy within 24 months prior to screening or metastatic
cancer
• Life expectancy less than 6 months
• Severe cognitive impairment (Mini Mental State Examination < 10)
• Any medical or other reason (e.g. known or suspected inability of the
patient to comply with the protocol procedure) in the judgement of
the investigators, that the patient is unsuitable for the study
• Unwilling to provide consent and those who cannot be followed-up
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During enrollment and at the two face to face follow
up visits blood and urine samples will be collected and
analysed for serum creatinine, urinary albumin and
albumin-to-creatinine ratio.
Telephone follow-up
At 6- and 18-month participants and/or caregivers will
be interviewed by phone to collect information on vital
and functional status and healthcare resource consump-
tion. Changes in medical history and adverse drug reac-
tions will also be collected.
Laboratory parameters and biomarkers
Serum creatinine measurement will be standardised to
Isotope-Dilution Mass Spectrometry at local level, when
the method is available. Creatinine-based eGFR will be
calculated using the Berlin Initiative Study 1 (BIS1)
equation, which is the only method specifically devel-
oped in a population older than 70 years [54]. ESRD will
be defined as GFR < 15 mL/min/1.73 m2 or dialysis [55].
In case of unavailability of standardized creatinine meth-
odology at local level, this measurement will be made by
INRCA laboratories afterwards. The panel of laboratory
parameters to be measured at baseline, 12-month and
24 months by local laboratories will also include:
complete blood cells count, lipids profile, electrolytes,
nutritional status, and urine analysis.
The project will also include the collection of blood and
urine samples to investigate existing and innovative bio-
markers of kidney function. Existing biomarkers of CKD
like Cystatin C (CysC) [56], β-Trace protein (BTP), also
known as lipocalin prostaglandin D2 synthase [57, 58]
Beta2-microglobulin [59] will be measured using published
and established methods. Potential and new biomarkers will
be also evaluated. Furthermore, the evaluation of experi-
mental kidney damage biomarkers as well as untargeted
analysis of metabolomics in serum and urine is currently be
performed in ULSAM [60] and PIVUS [61] studies, in
order to identify additional kidney damage biomarkers that
may be validated in the SCOPE project. Table 3 shows an
overview on current, alternative and innovative biomarkers
for CKD whose applicability in old age will be investigated
within the SCOPE project.
The assessment of selected genetic and epigenetic pa-
rameters involved in hallmarks of aging will be also car-
ried out to investigate their relationship with kidney
function. This latter assessment will be limited to partic-
ipants who signed a separate informed consent (patients
not giving informed consent for genetic and epigenetic
analysis will be retained in the main cohort study), and
will include: DNA methylation, polymorphisms of mito-
chondrial DNA, polymorphisms of genes coding for pro-
and anti-inflammatory cytokines (IL-6, IL-1, TNF-alpha,
Table 2 Comprehensive Geriatric Assessment domains tested
during the SCOPE project
• Basic (ADL) and Instrumental Activities of Daily Living (IADL)/self-
reported disability [39, 40]
• Mini Mental State Examination (MMSE)/cognitive status [41]
• 15-items Geriatric Depression Scale (GDS)/mood [42]
• Cumulative Illness Rating Scale (CIRS)/overall comorbidity [43]
• History of falls and incident falls
• Vision and hearing impairment will be coded on a scale from 0
(adequate) to 4 (no vision/hearing present) [44].
• Lower urinary tract symptoms (LUTS): The presence of LUTS will be
ascertained by asking the patient to rate on a 5-point (0–4) Likert
scale how big a problem, if any, has each of the following items been
during the last 4 weeks: 1. Dripping or leaking urine, 2. Pain or burn-
ing in urination, 3. Bleeding with urination, 4. Weak urine stream or
incomplete emptying, 5. Waking up to urinate, 6. Need to urinate fre-
quently during the day [45].
• Nutritional status: anthropometric parameters (calf circumference, arm
circumference, Body mass index (kg/m2), waist-hip ratio, waist-to-
height ratio), Mini Nutritional Assessment (MNA) [46] and 24-h dietary
recalla [47].
• Short Physical Performance Battery (SPPB) [48].
• Grip strength [49] measured by using JAMAR hydraulic
dynamometer.
• Bioelectrical impedance analysis (BIA)b [50] Muscle mass will be
calculated using the Janssen et al. equation [51], using the
instrument Akern BIA101.
• Health related quality of life will be rated by the Euro-QoL 5D.
aData obtained from the 24-h dietary recall will be analyzed using nutritional
databases suitable for the patient’s country. Following the analysis, a detailed
report (containing levels of consumption of various nutrients and energy) will
be available. This level will be compared with recommended levels of intake
bBIA will not be performed in patients with pacemaker or implantable
cardioverter defibrillator
Table 3 Biomarkers research in the SCOPE project
Current screening
methodsa
Alternative screening
methodsb
Innovative screening
methodsb
Serum creatinine Serum cystatin C Serum fibroblast growth
factor 23
Creatinine-based
eGFR
Serum β-trace
protein
Serum and urinary soluble
TNF receptor 1
Urinary albumin Serum β2-
microglobulin
Seerum and urinary soluble
TNF receptor 2
Albumin-to-
creatinine ratio
Serum and urinary
osteopontin
Serum penthraxin 3
Serum and urinary
endostatin
Serum and urinary TIM-1
(KIM-1)
Serum TRAIL R2
Serum and urinary
endostatin
acurrent screening measures will be assessed at local laboratories and are
immediately available after enrollment and follow-up visits;
balternative and innovative screening measures will be centrally assessed and
will be concealed until data analysis
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IL-10, IL-2, IL-17, IL-8) and chemokines (MCP-1 and
RANTES), polymorphisms associated with molecules in-
volved in the pathogenesis of metabolic and neurodegen-
erative diseases such as insulin and IGF-1 signaling
pathway and APOE, Klotho, mTOR, and whole genome
analysis by Affymetrix Chip Array 6.0.
Measured glomerular filtration rate
The assessment of measured glomerular filtration rate
(mGFR) will be performed by single-dose inulin clear-
ance [62, 63]. Participants will be asked to sign a separ-
ate informed consent to participate in this sub-study,
while those not giving their consent will be retained in
the main cohort study. The objective of this sub-study
will be the derivation of new eGFR equation(s) based on
already known and/or novel biomarkers. The accuracy
of new equation(s) in predicting mGFR will represent
the primary study endpoint. Accuracy will be assessed
by P30 (percentage of estimates within 30% of the
mGFR). A sample of 400 participants will enable us to
detect a difference of 2% in P30 between the new equa-
tions (based on the innovative and novel biomarkers)
and the BIS equations, with significance level 0.05 and
power 0.8 (considering a 1-sample and 1-sided test). In
addition, we have evaluated that the sample will be suffi-
cient to detect a statistically significant difference in 4,3
points in the Area under the ROC curve using the new
equation(s) for discriminating participants below the
critical threshold of 60 ml/min/1.73 m2. Finally, the
availability of mGFR in a subgroup of participants en-
rolled in the study will be used to investigate the rela-
tionship between innovative biomarkers and objectively
measured kidney function.
Study endpoints
The primary study endpoints will be the rate of eGFR
decline and the incidence of ESRD.
The secondary endpoints will include measures of
conventional and geriatric outcome measures, such as:
rate of CKD complications (anemia, hyperphosphatemia,
acidosis, hypoalbuminemia, hyperparathyroidism, hyper-
kaliemia); rate of major comorbidities (e.g. hypertension
and CV diseases) [43]; overall and CV mortality; adverse
drug reactions (ADRs); self-reported disability and ob-
jectively measured physical performance decline [39, 40,
48]; cognitive impairment [41]; depression [42]; malnu-
trition/undernutrition [46, 47]; health-related quality of
life [52]; healthcare resource consumption, including the
estimation of caregiver burden [53].
Informations on vital status during follow-up will be ob-
tained by interviewing the patients and/or their formal and/
or informal caregivers. For mortality during the follow-up
period, date, place and cause of death will be retrieved by
certificates of death exhibited by relatives or caregivers.
Data management and statistics
The SCOPE project will enroll a total of 2450 participants.
On the basis of the primary end-points, a sample of 1900
patients will be able to differentiate between two equally
sized subgroups according to a standardized difference in
yearly rate of GFR decline of 0.13 mL/min/1.73m2 with a
power of 80%. The same sample size allows to detect a
hazard ratio of 1.2 in time-to-event analyses with 80%
power for incidence of ESRD. Thus, even a 20% drop out
rate will not affect statistical power of the study.
Every effort will be made to collect all data at the spe-
cified time points. In the case of missing (and not recov-
erable) data on primary endpoints, we will make the
assumption that data are missing completely at random.
Analyses will be carried out applying the list-wise dele-
tion of cases with missing values in order to obtain un-
biased estimations. Multiple imputation of missing data
will be applied only for secondary endpoints and
co-variates when found appropriate.
For continuous outcomes, generalized mixed models
will be used while for dichotomous outcomes, random
effect logistic or Cox regression will be applied. Effect
modification by age and gender will be investigated
using multiplicative interaction analyses.
Relevant exposure and co-variates will be selected
based on plausible underlying hypothesis. Directed acyc-
lic graphs may be used in order to create parsimonious
multivariable models with minimized confounding. If
appropriate, repeated measurements of exposure and
co-variates will be included in the models.
Economic monitoring
The economic analysis of the SCOPE project will in-
clude: i) cost of screening/diagnosis; ii) cost of follow-up
(e.g. pharmacological treatment, specialist visits, labora-
tory visits over the 2-year follow-up); iii) cost of CKD
complications (e.g. emergency room access, hospital ad-
mission, haemodialysis, etc.); iv) other health-related
costs (e.g. hospital out-patient care referrals, nursing
home placements, use of home care services). With this
analysis, it will be possible to determine main predictors
of costs in CKD using multivariate regression and to es-
tablish cost-effective ratio of the intervention (overall
healthcare costs, divided by efficacy, expressed as sur-
vival or quality-adjusted survival).
In order to assess the cost-benefit profile of the
screening program on a longer time horizon, clinical
and economic results of the SCOPE project will be used
to run a projection (10–15 years) using Markov model-
ling. The analysis consists in evaluating a hypothetical
cohort of CKD patients, whose healthcare status is cate-
gorized into different initial Markov states, based on
CKD biomarkers. Patients can move from one state to
another, according to certain probabilities that will be
Corsonello et al. BMC Nephrology  (2018) 19:260 Page 5 of 9
derived from the SCOPE project, and can develop com-
plications, such as cardiovascular morbidity, renal failure
and need of dialysis, CKD related and non-related death.
Discussion
The SCOPE study is one of the largest prospective ob-
servational cohort studies aimed at screening for CKD
among older persons across Europe. The current paper
outlines the study protocol including statistical analysis
of data, risk prediction modeling and economic evalu-
ation of costs arising from CKD during the advanced
ageing process.
The strength of the protocol outlined in this paper is
the real life setting for recruitment of participants. All
persons with age ≥ 75 years attending the outpatient ser-
vices at participating institutions will be requested to
participate in the study. No other inclusion criteria will
be considered. This seems the primary strength of the
SCOPE study. The collection of real life data in a longi-
tudinal fashion over a two- years period of time will
allow insight on the impact of renal function on the
management and advanced care planning of older sub-
jects prone to renal impairment.
It is expected that many of the participants enrolled
will be affected by multimorbidity [64]. The impact of
disease clusters and management strategies from experts
in the field of nephrology and geriatrics will open access
to comparative effectiveness analysis of data and inter-
ventions [65]. People older than 75 years or people with
impaired renal function have so far been rarely included
into clinical trials. Aging population heralds a new geri-
atric “reality”, namely an increase in older adults with
CKD. Conversely, many older adults are living healthy
and active, even with several chronic conditions. In this
context longitudinal epidemiological studies are ex-
tremely valuable tools in observational research and have
many uses and strengths [66].
Multimorbidity, and in this context CKD have been
shown to impact functional status, especially of older pa-
tients [66]. The systematic use of a CGA makes possible
the investigation of multiple domains of health status in
older persons. CGA is part of clinical practice of Geriat-
ric Medicine [67] and is also useful in research investi-
gating consequences of CKD [68, 69] since it has been
shown to affect different kind of outcomes relevant to
older people. The inclusion of functional domains, as re-
cently postulated by the World Health Organization
(WHO) [70] in the design of screening models for CKD
in older persons aligns the SCOPE projects with future
demands for all Health Care systems around the globe
[71, 72]. Health care is currently provided and funded
on a disease-centered approach in many health care sys-
tems. The inclusion of CGA in the longitudinal evalu-
ation of study participants of the SCOPE project will
allow a more patient-centered and individualized ap-
proach for screening and advanced care planning for
older subjects prone to kidney function decline [31, 69].
Furthermore, the search for biomarkers which are less
influenced by muscle mass and more accurate in pre-
dicting outcomes compared to circulating creatinine is
of special interest and will be further investigated. Thus,
combining the use of CGA and the investigation of
novel and existing independent biomarkers in within the
SCOPE project, could help in building new evidence in
the development of recommendations and guidelines for
a patient-centered approach in the screening and man-
agement of older people at risk for CKD.
The alignment of an economic evaluation of care path-
ways and histories of study participants during the study
period will give new input for care providers and planners
in different health care and funding systems. Inclusion of
costs of screening to achieve accurate diagnosis of CKD
and related follow-up costs (e.g. pharmacological treat-
ment, specialist visits, laboratory visits over the 2-year
follow-up) will answer current call for actions coming
from different bodies [73]. The focus on CKD related con-
sumption of healthcare resources (e.g. emergency room
access, hospital admission, hospital out-patient care refer-
rals, nursing home placements, use of home care services
and others) using Markov modelling will provide key in-
formation for developments in public health.
Major drawback or limitation of the project is the lack of
standardized management and care plans for older people
currently available for all participating centres. Centres en-
rolling participants in the SCOPE projects are highly experi-
enced in the management of older multimorbidity subjects
at risk for renal impairment and related clinical complica-
tions, including changes in functional status. Guidelines on
CKD management are mainly disease-centred and put a
focus on morbidities and mortality. It is to be foreseen that
the care pathways for participants will therefore still be tai-
lored individually and according to needs, driven by expert-
ise of staff in the participating centres. However, important
information may be expected though, as the implementa-
tion of the CGA per se into care pathways has already been
proven effective [67]. It seems noteworthy that the individu-
alized care approach during complex care management of
older subjects is part of daily routine in geriatric medicine.
Alignment of care processes along CGA results seems feas-
ible in the context of current scientific evidence.
In conclusion, the SCOPE project will close essential
gaps in the care of older people with declining kidney
function. Due to the extremely comprehensive study set-
ting and data analysis it is to be expected that evidence
arising from the SCOPE project will impact the manage-
ment of older people suffering from CKD, as well as the
quality of care delivered for older subjects at risk for
CKD in daily routine. The high quality of data retrieved
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will however, also open doors for new research and
innovation in the field of nephrology and geriatrics.
Building on solid evidence arising from the current pro-
ject, SCOPE will support the development of European
recommendations and guidelines, as well as a European
education program in the field of screening and manage-
ment of CKD in older adults across Europe.
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